Matthew Keller
Stock Analyst at H.C. Wainwright
(0.07)
# 4,752
Out of 5,051 analysts
101
Total ratings
21.8%
Success rate
-22.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Keller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GYRE Gyre Therapeutics | Reiterated: Buy | $18 | $6.87 | +162.20% | 12 | Oct 5, 2026 | |
| KYNB Kyntra Bio | Reiterated: Buy | $43 | $6.12 | +602.61% | 16 | Oct 5, 2026 | |
| ACXP Acurx Pharmaceuticals | Reiterated: Buy | $31 | $1.28 | +2,321.88% | 13 | Sep 29, 2026 | |
| ECOR electroCore | Reiterated: Buy | $18 | $9.28 | +93.97% | 1 | Sep 21, 2026 | |
| PHIO Phio Pharmaceuticals | Reiterated: Buy | $14 | $0.922 | +1,418.44% | 10 | Aug 27, 2026 | |
| SXTP 60 Degrees Pharmaceuticals | Reiterated: Hold | n/a | $0.9156 | - | 6 | Aug 18, 2026 | |
| GALT Galectin Therapeutics | Reiterated: Buy | $11 | $3.87 | +184.24% | 11 | Aug 14, 2026 | |
| IFRX InflaRx | Reiterated: Buy | $8 | $1.59 | +403.14% | 11 | Aug 6, 2026 | |
| MCRB Seres Therapeutics | Reiterated: Buy | $12 | $2.68 | +347.76% | 3 | Aug 5, 2026 | |
| GRI GRI Bio | Reiterated: Buy | $10 | $1.57 | +536.94% | 9 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.000001 | - | 5 | Mar 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $23.25 | - | 4 | Oct 30, 2025 |
Gyre Therapeutics
Oct 5, 2026
Reiterated: Buy
Price Target: $18
Current: $6.87
Upside: +162.20%
Kyntra Bio
Oct 5, 2026
Reiterated: Buy
Price Target: $43
Current: $6.12
Upside: +602.61%
Acurx Pharmaceuticals
Sep 29, 2026
Reiterated: Buy
Price Target: $31
Current: $1.28
Upside: +2,321.88%
electroCore
Sep 21, 2026
Reiterated: Buy
Price Target: $18
Current: $9.28
Upside: +93.97%
Phio Pharmaceuticals
Aug 27, 2026
Reiterated: Buy
Price Target: $14
Current: $0.922
Upside: +1,418.44%
60 Degrees Pharmaceuticals
Aug 18, 2026
Reiterated: Hold
Price Target: n/a
Current: $0.9156
Upside: -
Galectin Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $11
Current: $3.87
Upside: +184.24%
InflaRx
Aug 6, 2026
Reiterated: Buy
Price Target: $8
Current: $1.59
Upside: +403.14%
Seres Therapeutics
Aug 5, 2026
Reiterated: Buy
Price Target: $12
Current: $2.68
Upside: +347.76%
GRI Bio
May 14, 2026
Reiterated: Buy
Price Target: $10
Current: $1.57
Upside: +536.94%
Mar 30, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.000001
Upside: -
Oct 30, 2025
Downgraded: Hold
Price Target: n/a
Current: $23.25
Upside: -